Anti-RSV Recombinant Antibody (Palivizumab) (CAT#: TAB-009)

Recombinant monoclonal antibody to Human RSV. Palivizumab is a monoclonal antibody produced by recombinant DNA technology. It is used in the prevention of respiratory syncytial virus (RSV) infections. It is recommended for infants that are high-risk because of prematurity or other medical problems such as congenital heart disease. Palivizumab is a humanized monoclonal antibody (IgG) directed against an epitope in the A antigenic site of the F protein of RSV.

Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Datasheet
  • MSDS
  • COA

Figure 1 RSV neutralization, F glycoprotein recognition, and crystal structure of human antibody D25 in complex with the prefusion RSV F trimer.

Figure 1 RSV neutralization, F glycoprotein recognition, and crystal structure of human antibody D25 in complex with the prefusion RSV F trimer.

The prefusion conformation of RSV F is metastable, and when expressed in a soluble form readily adopts the postfusion state; a number of potent antibodies, including D25, bind to a newly revealed antigenic site at the top of the prefusion F glycoprotein. (A) RSV neutralization by antibodies. Palivizumab is the U.S. Food and Drug Administration (FDA)–approved prophylactic antibody thatprevents severe RSV disease. (B) Enzyme-linked immunosorbent assay measuring antibody binding to postfusion F glycoprotein. For (A) and (B), data are representative of multiple independent experiments. (C)D25-RSVFtrimercrystal structure in ribbon and molecular surface representations. One protomer of the F glycoprotein trimer is shown as ribbons and colored as a rainbow from blue to red, N terminus of F2to C terminus of F1, respectively. Molecular surfaces are shown for the other two F protomers, colored pink and green. The D25 Fab bound to the F protomer shown in ribbons is also displayed in ribbon representation, with the heavy chain colored red and light chain colored gray. The other D25 Fabs are colored the same, but shown in surface representation.

McLellan, J. S., Chen, M., Leung, S., Graepel, K. W., Du, X., Yang, Y., ... & Kumar, A. (2013). Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science, 340(6136), 1113-1117.

Figure 2 HighlyeffectiveRSVneutralizing antibodies target a site at the membranedistal apex of the prefusion F trimer.

Figure 2 HighlyeffectiveRSVneutralizing antibodies target a site at the membranedistal apex of the prefusion F trimer.

(A) The ability of antibodies to block D25 binding to RSV-infected cells was measured as a function ofantibody concentration. (B)AnalysisofRSVF-Fabcomplexesbynegative-stain electron microscopy (EM): Reprojection of a 12 Å slice through the crystal structure of RSV F + D25 Fab filtered to 10 Å resolution (left). A slice was used to emphasize visibility of the F glycoprotein cavity. Aligned average of 263 particles of RSV F + D25 Fab (middle left). Aligned average of 550 particles of RSV F + AM22 Fab (middle right). Aligned average of 171 particles of RSV F + 5C4 Fab (right). Scale bar, 50 Å. (C) Fusion inhibition and (D)attachmentinhibition activity for antibodies targeting antigenic site Ø and F-specific antibodies targeting other antigenic sites. For the attachment-inhibition assay, heparin was usedasapositivecontrol.Datain(A),(C),and(D)are representative of multiple independent experiments.

McLellan, J. S., Chen, M., Leung, S., Graepel, K. W., Du, X., Yang, Y., ... & Kumar, A. (2013). Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science, 340(6136), 1113-1117.

Figure 3 Anti-RSV F antibodies identified from Morphosys HuCAL GOLD® phage display libraries.

Figure 3 Anti-RSV F antibodies identified from Morphosys HuCAL GOLD® phage display libraries.

Heavy chain C-terminal 6xHis tagged antigen specific bivalent Fabs were purified with Ni-NTA column and then tested in ELISA binding to RSV prefusion and postfusion F proteins. (A) Antibodies preferentially binding to RSV postfusion F protein; (B) Antibodies binding to both RSV postfusion and prefusion F proteins; (C) antibody binding specifically to RSV prefusion F protein. Full-length human IgG1 D25 (prefusion F specific) and palivizumab (binding to both prefusion and postfusion F) were used as control antibodies in the above experiments.

Chen, Z., Zhang, L., Tang, A., Callahan, C., Pristatsky, P., Swoyer, R., ... & DiStefano, D. (2016). Discovery and characterization of phage display-derived human monoclonal antibodies against RSV F glycoprotein. PloS one, 11(6), e0156798.

Figure 4 Characterization of mAbs 2E1 and 3B1.

Figure 4 Characterization of mAbs 2E1 and 3B1.

(A-B) ELISA analysis of 2E1 IgG (A) and 3B1 IgG (B) binding to RSV pre- (red circle) and postfusion F (blue square) proteins. (C-H) Surface plasmon resonance (SPR) analysis of 2E1 and 3B1 Fabs binding to pre- and postfusion RSV F proteins. RU = Resonance Units. Monovalent Fab antibody fragments were captured on the surface of a Series S Sensor Chip CM5 previously functionalized with Human Fab Binder. Prefusion or postfusion F protein diluted 2-fold serially starting at 100 nM or 200 nM was then injected over captured 2E1 (C) or 3B1 (F), respectively. To determine steady-state affinity, response levels at equilibrium were plotted over concentration of pre- (D) or postfusion F (G) protein. 50 nM of post- (E) or prefusion F (H) was injected to demonstrate the specificity of 2E1 binding to prefusion F and 3B1 to postfusion F. (I-K) SPR based competition analysis of 2E1 and 3B1 against palivizumab (I), D25 (J) and MPE8 (K) in binding to RSV prefusion F protein. RU = Resonance Units. Palivizumab and D25 were amine coupled to the surface of separate flow channels of a CM5 chip. A third flow channel was subjected to amine coupling activation without an antibody and used for reference subtraction. Prefusion F (40 μg/mL) was then injected over all surfaces. After a brief stabilization period, 2E1, 3B1, or running buffer was injected to measure binding to sites not occupied by the capturing antibody (palivizumab or D25). To assess competition to MPE8, the MPE8 antibody was captured (6000 RU, not shown) to flow channel 2 of a Biacore Sensor Chip Protein A. Prefusion F (40 μg/mL) was passed over channels 1 and 2 followed by 2E1 Fab, 3B1 Fab, D25 Fab and buffer to measure binding to sites not occupied by MPE8. (L) Bio-Layer Interferometry (BLI) based competition experiment of 3B1 IgG against site I antibody 131-2a. Palivizumab (blue) is able to bind to postfusion F protein in an Octet sandwich competition assay using 131-2a as the capture antibody, but antibody 3B1 (red) does not bind.

Chen, Z., Zhang, L., Tang, A., Callahan, C., Pristatsky, P., Swoyer, R., ... & DiStefano, D. (2016). Discovery and characterization of phage display-derived human monoclonal antibodies against RSV F glycoprotein. PloS one, 11(6), e0156798.

Figure 5 Inactivation of RSV by UV or pretreatment with palivizumab (an anti-RSV F protein Ab) completely abolishes the expression of COX-2 mRNA and protein.

Figure 5 Inactivation of RSV by UV or pretreatment with palivizumab (an anti-RSV F protein Ab) completely abolishes the expression of COX-2 mRNA and protein.

A, Analysis of COX-2 mRNA expression. For the UV-inactivated RSV study, cells were harvested at 24–48 h. Palivizumab-treated RSV (400 ug/ml palivizumab, 1 h incubation at room temperature) or control, untreated, RSV was incubated with the cells for 48 h. RSV F protein mRNA expression is shown as a control for viral replication. B, Western blot analysis of the expression of COX-2 protein. The virus preparations used were RSV alone (RSV), RSV inactivated by UV (UV-RSV), RSV incubated for 1 h with palivizumab (400 ug/ml), or RSV treated with a control unrelated mAb (C mAb RSV). RSV was used at an equivalent of 0.5 m.o.i. in all cases. Data shown are representative of four independent experiments.

Richardson, J. Y., Ottolini, M. G., Pletneva, L., Boukhvalova, M., Zhang, S., Vogel, S. N., ... & Blanco, J. C. (2005). Respiratory syncytial virus (RSV) infection induces cyclooxygenase 2: a potential target for RSV therapy. The Journal of Immunology, 174(7), 4356-4364.


Specifications

  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Host Species
  • Mouse
  • Derivation
  • Humanized (from mouse)
  • Type
  • IgG1 - kappa
  • Specificity
  • Tested positive against native RSV antigen
  • Species Reactivity
  • RSV
  • Applications
  • IF, IP, Neut, FuncS, ELISA, FC, WB
  • Trade name
  • synagis
  • CAS
  • 188039-54-5
  • Generic Name
  • Palivizumab
  • Biological Half-Life
  • 18-20 days
  • ATC Code
  • J06BB16
  • DrugBank
  • DB00110
  • UNII
  • DQ448MW7KS
  • ChEMBL
  • CHEMBL1201586
  • Related Disease
  • Respiratory Syncytial Virus (RSV) disease

Product Property

  • Purity
  • >97%, by SDS-PAGE under reducing conditions and visualized by silver stain.
  • Storage
  • Store it under sterile conditions at -20°C upon receiving. Recommend to pack the protein into smaller quantities for optimal storage.

Applications

  • Application Notes
  • The RSV F antibody has been reported in applications of Neut, Inhib, ELISA, SPR, WB.

Target

  • Alternative Names
  • Palivizumab;synagis;188039-54-5;MEDI-493;humanized MAb1129;DB00110RSV;F;Fusion protein (F);NP_044596.1;UniProt ID: O09720;O09720;Entrez: 1494475;Entrez Gene: 1494475;Gene ID: 1494475;Palivizumab;Synagis;Palivizumab;Synagis

Related Resources

  • Biosimilar Overview
Please refer to Palivizumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Palivizumab.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Palivizumab"

Afuco™ Anti-RSV F ADCC Recombinant Antibody (Palivizumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to Human RSV. Palivizumab is a monoclonal antibody produced by recombinant DNA technology. It is used in the prevention of respiratory syncytial virus (RSV) infections. It is recommended for infants that are high-risk because of prematurity or other medical problems such as congenital heart disease. Palivizumab is a humanized monoclonal antibody (IgG) directed against an epitope in the A antigenic site of the F protein of RSV.

See other products for "RSV F"

Select a product category from the dropdown menu below to view related products.
Please select product type
Humanized Antibody Human Antibody Recombinant Antibody scFv Fragment Antibody Fab Fragment Antibody Mouse Antibody ADCC Enhanced Antibody MHC Tetramer for Virology
CAT Product Name Application Type
TAB-709 Anti-RSV glycoprotein F Recombinant Antibody (Motavizumab) IF, IP, Neut, FuncS, ELISA, FC, WB IgG1 - kappa
MRO-1209LC Anti-HRSV F Recombinant Antibody (MEDI-493) ELISA, Neut, PK Humanized antibody
MRO-1209LC-S(P) Anti-HRSV F Recombinant Antibody scFv Fragment (MEDI-493) ELISA Humanized antibody
MRO-1209LC-F(E) Anti-HRSV F Recombinant Antibody Fab Fragment (MEDI-493) ELISA Humanized antibody

Customer Reviews and Q&As

Submit a review or a question

There are currently no Customer reviews or questions for TAB-009. Click the button above to contact us or submit your feedback about this product.

Cite This Product

To accurately reference this product in your publication, please use the following citation information:

(Creative Biolabs Cat# TAB-009, RRID: AB_3111737)

Copy citation

Popular products with customers


For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

  • 0
  • 0
Cart
    Go to compare

    Go to compare